Propofol
Overview
Propofol is an intravenous general anesthetic whose main component is 2,6-diisopropylphenol. First developed in the United Kingdom in 1977 and introduced clinically in 1986, it is widely used worldwide for induction and maintenance of anesthesia, sedation in the intensive care unit (ICU), and sedation during various procedures. Propofol has a rapid onset of action (approximately 30–60 seconds) and a short recovery time, earning it the nickname "milk of amnesia." However, it has side effects such as respiratory depression, hypotension, and injection pain, and misuse or abuse can lead to addiction and death, so it is strictly regulated as a medical narcotic.
Main Content
Pharmacology and Mechanism of Action
Propofol binds to the beta subunit of the GABA-A receptor, opening chloride ion channels and inducing hyperpolarization of neurons, thereby inhibiting the central nervous system. This results in loss of consciousness, amnesia, muscle relaxation, and sedation. It has almost no analgesic effect, so additional analgesics are needed for procedures involving pain.
Clinical Uses
- Anesthesia induction: Intravenous administration of 1.5–2.5 mg/kg causes loss of consciousness within 30–60 seconds. Used for endotracheal intubation, etc.
- Anesthesia maintenance: Continuous intravenous infusion (100–200 μg/kg/min) maintains general anesthesia.
- Sedation: Used in small doses for conscious sedation during endoscopy, dental procedures, cosmetic procedures, etc.
- ICU sedation: Maintains sedation in patients on mechanical ventilation.
- Status epilepticus: Used as a second-line treatment.
Side Effects and Risks
- Respiratory depression: Dose-dependently inhibits the respiratory center, potentially causing apnea. Airway equipment and mechanical ventilation must be prepared.
- Hypotension: Vasodilation and myocardial depression lower blood pressure. Caution is needed especially in elderly and hypovolemic patients.
- Injection site pain: Approximately 30–70% of patients report pain upon intravenous injection. Alleviated by mixing with lidocaine, etc.
- Propofol infusion syndrome (PRIS): Can occur with prolonged high-dose infusion (>4 mg/kg/h). Progresses to metabolic acidosis, rhabdomyolysis, heart failure, renal failure, and death. Risk increases in children, critically ill patients, and those with lipid metabolism disorders.
- Misuse and addiction: Propofol can induce euphoria, hallucinations, and sexual arousal, with reports of abuse by medical personnel and the general public. Overdose can lead to respiratory arrest and cardiac arrest, resulting in death. It is classified as a psychotropic substance under narcotics control laws.
Pharmacokinetics
- Distribution: Highly lipophilic, rapidly distributes to the brain. Distribution half-life: 2–4 minutes.
- Metabolism: Primarily metabolized in the liver; metabolites are excreted by the kidneys.
- Elimination half-life: Initial 30–60 minutes, terminal 3–12 hours. May accumulate with prolonged infusion.
- Excretion: Approximately 88% of metabolites are excreted in urine.
Formulation and Administration
- Formulation: 1% or 2% lipid emulsion (containing soybean oil, egg lecithin, glycerol). White milky liquid.
- Storage: Store at 4–25°C; use within 6 hours after opening. If refrigerated, rewarm before use.
- Route of administration: Intravenous injection (bolus or continuous infusion). Not for intramuscular injection.
Contraindications and Precautions
- Contraindications: Hypersensitivity to propofol or lipid components, severe hypotension, shock, uncontrolled epilepsy.
- Precautions: Elderly, children, pregnant women (especially first trimester), cardiovascular disease, respiratory disease, lipid metabolism disorders, electrolyte imbalances.
Recent Trends
Key trends related to propofol as of 2024–2025 are as follows.
1. Strengthened regulation of misuse: In South Korea and many other countries, propofol is classified as a narcotic, and prescription and administration records are computerized to prevent non-medical use. In 2024, South Korea expanded the system requiring medical institutions to report propofol usage in real time to the local health center.
2. Development of new formulations: To reduce stability issues of lipid emulsions and the risk of bacterial growth, research is ongoing on new formulations with lower lipid content or non-emulsion propofol analogs. For example, fospropofol, a prodrug that is water-soluble, causes less injection pain and has a lower risk of bacterial growth, but its clinical use is limited.
3. Expansion of sedation applications: As demand for conscious sedation using propofol increases in endoscopy, dental, and cosmetic procedures, guidelines for use by non-anesthesiologists are being developed. In 2025, the American Society of Anesthesiologists (ASA) published updated recommendations on propofol use for sedation, re-emphasizing the importance of patient monitoring and emergency preparedness equipment.
4. Research on propofol infusion syndrome: Active research is underway to elucidate the pathophysiology of PRIS and develop early diagnostic biomarkers. Recent studies have identified mitochondrial dysfunction and inhibition of fatty acid oxidation as key mechanisms, and therapeutic agents targeting these are being developed.
5. Changes in social awareness: Following celebrity deaths (e.g., Michael Jackson, Korean celebrities), public awareness of propofol has increased, and within the medical community, education on appropriate use and addiction prevention has been strengthened.
Related Topics
- [[Anesthetic]]
- [[Psychotropic substance]]
- [[ICU sedation]]
- [[Propofol infusion syndrome]]
- [[Medical narcotics management]]
---
AI auto-generated document · Improved by the community